Business Wire

GIGABYTE

Share
GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On

GIGABYTE Technology, a leading IT innovator, is at the forefront of advancing global industries through cloud and AI computing systems, enhancing user experiences through hardware innovation. At COMPUTEX 2024, GIGABYTE unveils groundbreaking products poised to define the AI era.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240517872510/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

GIGABYTE Showcases a Whole Lot of Computing Power at COMPUTEX, Taking the AI-driven New Evolution Head-On (Graphic: Business Wire)

Building on last year’s success, GIGABYTE looks to solidify its AI leadership with the theme “ACCEVOLUTION,” reflecting the increasing demand for computing and GIGABYTE’s ability to “accelerate the next evolution.” With its largest-ever presence at COMPUTEX, GIGABYTE’s booth stands as the largest single-brand exhibit. Showcasing a wide range of products, solutions, and applications aligned with the AI trend, GIGABYTE covers key tech trends including AI computing, advanced connectivity, future mobility, immersive reality, sustainability, and innovation.

GIGABYTE’s remarkable advancements in AI server development in recent years have garnered widespread attention, as GIGABYTE introduced the G593-SD0, the world’s first and only NVIDIA-certified 5U AI server to efficiently support the HGX™ H100 8 x SXM5. GIGABYTE further expands its super AI server lineup with ARM-based AI servers featuring the next-generation Grace Hopper™ superchip, and AI servers supporting AMD’s next-gen superchips MI300X GPU and MI300A APU. This year, on top of the upgraded H200 GPU, with NVIDIA unveiling the Blackwell architecture, GIGABYTE will showcase ahead of schedule at its booth the latest high-density servers compatible with GPUs such as B100 and B200. The highly-anticipated GB200 will also be demonstrated in a liquid-cooled cabinet as GB200 NVL72, acting as one massive GPU that can achieve 30 times the inference performance of the same amount of H100 GPUs. This allows visitors not only to witness these innovations firsthand but also to engage in discussions with professionals about the future of AI development and computing deployment.

As AI becomes ubiquitous, computing demand rises sharply in large data centers and AI startups. At this year’s COMPUTEX, GIGABYTE presents GIGA POD, a scalable rack integration solution, designed to meet data center-level deployments. Beyond showing GIGA POD’s comprehensive hardware and software integration and AI training optimization environments, on-site demonstrations will highlight its performance leadership and deployment flexibility.

GIGABYTE’s AI development encompasses GPU parallel computing, data storage, and network transmission in data centers. GIGABYTE’s R&D prowess is evident in industry-leading thermal and mechanical design, while modular design enables product diversity, speeding up time-to-market. At the booth, find servers for cloud to edge computing, high-performance to high-density storage, and computing options for SMBs and micro-enterprises, including DIY server motherboards tailored to AI development at various scales.

GIGABYTE’s green computing complements AI advancements perfectly. Innovations like Direct Liquid Cooling and Immersion Cooling redefine performance and efficiency, offering comprehensive setups for servers and cabinets. This enables servers with the latest chips from AMD, Intel, and NVIDIA to surpass traditional cooling limits, enhancing heat dissipation and computational density while ensuring stability. GIGABYTE’s sustainability commitment is evident in immersion cooling solutions, supporting technological advancements with optimal power usage.

GIGABYTE presents both robust AI model training capabilities and practical AI applications through industrial-grade embedded computers. Demonstrations span smart factories with AI-enabled machine vision and high-stability embedded computers for remote control, as well as retail bars utilizing panel PCs combined with AI recognition and big data analysis. Advancements in AI and next-generation CPU/GPU also bolster smart automotive applications, enhancing ADAS and in-vehicle Telematics devices.

In the consumer PC market, GIGABYTE leads with AI-enhanced products like motherboards, graphics cards, and AI gaming laptops. These feature stable AI computing power and innovative capabilities such as the AI Nexus in the AORUS 16X gaming laptop, offering applications like AI Power Gear and AI Boost. At our booth’s AI experience area, visitors can explore the latest AI applications and real-time interactions, including NVIDIA ACE and ChatRTX, delving immersively into cutting-edge AI technologies.

GIGABYTE is bringing an impressive products portfolio to COMPUTEX, demonstrating its capacity to accelerate the next evolution of technology in this changing AI landscape, and its abundance of computing solutions driven by the connectivity and velocity of data and AI can elevate businesses and empower individuals to thrive in the extra-fast growing and development time.

Visit GIGABYTE’s COMPUTEX event page.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240517872510/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye